Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure?

Circulation

Volumn 105, Issue 15, 2002, Pages 1810-1815

  Bennett Richards, Katy ^a   Kattenhorn, M ^a   Donald, A ^a   Oakley, G ^a   Varghese, Z ^a   Rees, L ^a   Deanfield, J E ^a  

^a Vascular Physiology Unit   (United Kingdom)

Author keywords

Endothelium; Folic acid; Homocysteine; Renal failure

Indexed keywords

FOLIC ACID; GLYCERYL TRINITRATE; HOMOCYSTEINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO;

ADOLESCENT; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID OXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; NITROGLYCERIN; OXIDATIVE STRESS; VASODILATION; VASODILATOR AGENTS; VASOMOTOR SYSTEM;

EID: 0037117657     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000014417.95833.1D     Document Type: Article

References (35)

1. Atherosclerosis and arteriosclerosis in chronic renal failure
2. Physiology and biochemistry of endothelial function in children with chronic renal failure
3. Hyperhomocysteinemia: An independent risk factor for vascular disease
4. Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine study
5. Serum total homocysteine and coronary heart disease
6. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
7. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
8. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
9. The oxidant stress of hyperhomocyst(e)inemia
10. Premature cardiovascular disease in chronic renal failure
11. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
12. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease
13. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia
14. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients
15. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?
16. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
17. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients
18. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein
19. Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid
20. Report on management of renal failure in Europe, XXII, 1991
21. Clinical epidemiology of cardiovascular disease in chronic renal disease
22. Plasma homocysteine levels and mortality in patients with coronary artery disease
23. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
24. Hyperhomocyst(e)inaemia in children with chronic renal failure
25. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia: A randomized placebo-controlled trial
26. Carotid artery stiffness in patients with end-stage renal disease: No effect of long-term homocysteine-lowering therapy
27. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
28. Reversal of hyperhomocyst(e)inaemia in chronic renal failure: Is folic or folinic acid the answer?
29. Cardiovascular risks: New insights from Framingham
30. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility
31. Atherogenic lipids vascular dysfunction, and clinical signs of ischaemic heart disease
32. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
33. What we know and don't know about L-arginine and NO
34. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia